Facile fabrication of a novel hybrid nanoparticles by self-assembling based on pectin-doxorubicin conjugates for hepatocellular carcinoma therapy
Source abstract
Abstract
Hepatocellular carcinoma (HCC) is one of the greatest public health problems worldwide, and chemotherapy remains the major approach for the HCC treatment. Doxorubicin (DOX) is one of the anthracycline antibiotics but its clinical use is limited due to its severe cardiotoxicity. In this study, novel hybrid nanoparticles by self-assembling based on pectin-doxorubicin conjugates (PDC-NPs) were fabricated for HCC treatment. The stabilized structure of the PDC-NPs was characterized by methylene blue absorption, the size, zeta potential and the morphology, which was investigated by Zetasizer nanoparticle analyzer and transmission electron microscope (TEM), of nanoparticles. The PDC-NPs achieved a sustained and prolonged release ability, which was illustrated with in vitro drug release profiles, anti-cell proliferation study, cellular uptake assay and in vivo pharmacokinetics analysis. Biocompatibility of the PDC-NPs was assessed with bovine serum albumin (BSA) adsorption test, hemolysis activity examination and viability evaluation of human umbilical vein endothelial cells. Importantly, in vivo studies of the PDC-NPs, which were performed in the athymic BALB/c nude mice, demonstrated that the PDC-NPs significantly reduced the lethal side effect of DOX. Additionally, the H&E staining and serum biochemistry study further confirmed the excellent biological security of the PDC-NPs.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Hepatocellular Carcinoma Treatment and Prognosis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Hunan Province Cooperative Innovation Centre for Molecular Target New Drug Study, University of South China
Institute of Pharmacy & Pharmacology, University of South China
Funding
National Natural Science Foundation of China · Natural Science Foundation of Hunan province · University of South China
References (35)
Show source-provided references
1. 10.3322/caac.2133810.3322/caac.21338 ↗
2. Zamani P, Riahi MM, Momtaziborojeni AA, et al. Gankyrin: a novel promising therapeutic target for hepatocellular carcinoma. Artifi Cell Nanomed Biotechnol. 2017;1:1–13.
3. 10.1021/acs.accounts.7b0029410.1021/acs.accounts.7b00294 ↗
4. 10.1016/j.ijpharm.2016.08.03510.1016/j.ijpharm.2016.08.035 ↗
5. 10.1016/j.ijpharm.2012.08.00710.1016/j.ijpharm.2012.08.007 ↗
6. Pan JX, Chen G, Li JJ, et al. Isocorydine suppresses doxorubicin-induced epithelial-mesenchymal transition via inhibition of ERK signaling pathways in hepatocellular carcinoma. Am J Cancer Res. 2018;8:154–164.
7. 10.2174/09298670978880331210.2174/092986709788803312 ↗
8. 10.1016/0169-409X(95)00030-B10.1016/0169-409X(95)00030-B ↗
9. 10.3109/21691401.2013.76862710.3109/21691401.2013.768627 ↗
10. 10.7150/thno.2129710.7150/thno.21297 ↗
11. 10.1166/jbn.2017.240710.1166/jbn.2017.2407 ↗
12. 10.1166/jbn.2017.240610.1166/jbn.2017.2406 ↗
13. 10.1166/jbn.2017.238210.1166/jbn.2017.2382 ↗
14. 10.7150/thno.2298910.7150/thno.22989 ↗
15. 10.1166/nnl.2017.258910.1166/nnl.2017.2589 ↗
16. 10.1016/j.cclet.2017.01.00510.1016/j.cclet.2017.01.005 ↗
17. 10.1016/j.carbpol.2017.08.10710.1016/j.carbpol.2017.08.107 ↗
18. 10.1016/j.ejps.2017.10.03610.1016/j.ejps.2017.10.036 ↗
19. 10.1016/j.biomaterials.2017.07.03010.1016/j.biomaterials.2017.07.030 ↗
20. 10.2174/138161282288815120709562010.2174/1381612822888151207095620 ↗
21. 10.1039/C8RA01403E10.1039/C8RA01403E ↗
22. 10.1016/j.ejpb.2017.12.01710.1016/j.ejpb.2017.12.017 ↗
23. 10.1016/j.jconrel.2017.12.01510.1016/j.jconrel.2017.12.015 ↗
24. 10.1016/j.jconrel.2016.01.02010.1016/j.jconrel.2016.01.020 ↗
25. 10.1039/C4TB01611D10.1039/C4TB01611D ↗
26. Gershwin ME, Vierling JM, Manns MP. Liver immunology: principles and practice. 2nd ed. Germany: Springer; 2013.
27. 10.1016/S0169-409X(98)00006-410.1016/S0169-409X(98)00006-4 ↗
28. 10.1016/j.ejpb.2007.08.00110.1016/j.ejpb.2007.08.001 ↗
29. 10.1021/acsami.7b1449610.1021/acsami.7b14496 ↗
30. 10.1021/la901389v10.1021/la901389v ↗
31. 10.1021/mp400412c10.1021/mp400412c ↗
32. 10.1016/j.carbpol.2016.10.01910.1016/j.carbpol.2016.10.019 ↗
33. 10.1016/j.ijpharm.2006.05.01510.1016/j.ijpharm.2006.05.015 ↗
34. 10.1038/bcj.2012.1010.1038/bcj.2012.10 ↗
35. 10.1021/bm501382210.1021/bm5013822 ↗